<DOC>
	<DOCNO>NCT00960635</DOCNO>
	<brief_summary>This randomize , two-arm , placebo-controlled phase-2 trial determine whether daily intake 1,25-dihydroxy-vitamin D3 [ 1,25 ( OH ) 2D3 ] , improve beta cell function patient recently diagnose type 1 diabetes . The treatment consist daily oral administration 0.25 Âµg 1,25 ( OH ) 2D3 placebo 9 month equal follow-up time without supplementation . Fasting , peak AUC C-peptide concentration 2-hour mixed meal tolerance test measure begin study , well end treatment follow-up period month 9 18 . The null hypothesis difference 1,25 ( OH ) 2D3 treated subject placebo group AUC C-peptide month 18 .</brief_summary>
	<brief_title>Immunointervention With Calcitriol New-Onset Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<criteria>New onset Typ 1 diabetes ( &lt; 6 week insulin therapy ) Age 1839 year GADA and/or IA2A positive Kidney disease Pregnancy Lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>new-onset</keyword>
</DOC>